Katrina K. Bakken

Mayo Clinic, Rochester

Affiliated withMayo Clinic, Rochester

Research Area

Cancer Research

Biography

Katrina K. Bakken has not added Biography.
If you are Katrina K. Bakken and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro-oncology\| PubMed ID: 40230030	2025
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 41664821	2026
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24838527	2014
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25609063	2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Journal of the National Cancer Institute\| PubMed ID: 26615020	2016
Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 27196784	2016
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastom... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 28847917	2017
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 28947502	2017
Efficacy of Tesevatinib in -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Molecular cancer therapeutics\| PubMed ID: 33785646	2021
Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. Cancer research\| PubMed ID: 34016623	2021
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro-oncology\| PubMed ID: 34232318	2022
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neuro-oncology advances\| PubMed ID: 37324218	2023
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts. Molecular cancer therapeutics\| PubMed ID: 38224566	2024
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Science translational medicine\| PubMed ID: 38354228	2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of ... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 39284626	2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. Molecular cancer therapeutics\| PubMed ID: 39440433	2025
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628. Molecular cancer therapeutics\| PubMed ID: 39559836	2025
The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-oncology\| PubMed ID: 40163716	2025